top of page

Videnskabelige studier om mRNA

Evolution of Lymphadenopathy at PET MRI after COVID-19 Vaccination

Lymfadenopati

COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies Cross-Sectional Imaging Findings on MRI, CT, and PET-CT

Lymfadenopati

COVID-19 Vaccination–Associated Lymphadenopathy on FDG PET CT

Lymfadenopati

COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel, Analysis of 163 cases

Lymfadenopati

COVID‐19 post‐vaccination lymphadenopathy Report of cytological findings from fine needle aspiration biopsy

Lymfadenopati

Cervical lymphadenopathy following coronavirus disease 2019 vaccine clinical characteristics and implications for head and neck cancer services

Lymfadenopati

Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021

Lymfadenopati

A Case of Cervical Lymphadenopathy After Vaccination Against COVID-19

Lymfadenopati

The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large Population-Based Study

Myocarditis & Myopericarditis

The central role of natural killer cells in mediating acute myocarditis after mRNA COVID-19 vaccination

Myocarditis & Myopericarditis

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection.

Myocarditis & Myopericarditis

Temporal Association Between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis, A Case Report and Literature Review

Myocarditis & Myopericarditis

Takotsubo Cardiomyopathy After mRNA COVID-19 Vaccination

Myocarditis & Myopericarditis

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination

Myocarditis & Myopericarditis

SARS-CoV-2 vaccine and increased myocarditis mortality risk, A population based comparative study in Japan

Myocarditis & Myopericarditis

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

Myocarditis & Myopericarditis

SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17, A Stratified National Database Analysis

Myocarditis & Myopericarditis

Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England.pdf

Myocarditis & Myopericarditis

Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years.

Myocarditis & Myopericarditis

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Myocarditis & Myopericarditis
bottom of page